FREMONT, Calif., Nov 09, 2015 (GLOBE NEWSWIRE via COMTEX) --
Zosano Pharma Corporation ZSAN, +2.03% a clinical-stage specialty pharmaceutical company, today announced financial results for the three months ended September 30, 2015.
“We had a very eventful third quarter with updates on all programs. We are particularly pleased with our progress in building the depth and breadth of our organization and our clinical development advancements,” said Vikram Lamba, Zosano’s Chief Executive Officer. “With the successful completion of our Phase 2 clinical trial on ZP-Glucagon with efficacy data demonstrating the patch’s rapid onset of action - and positive Phase 1 clinical trial data on ZP-Triptan showing good safety performance and achieving rapid absorption consistently across multiple doses of our patch, we have repeatedly demonstrated the ability of our technology to deliver product candidates with a fast onset.”
Help employers find you! Check out all the jobs and post your resume.
